Compare OLED & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | ACAD |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | 1996 | 2000 |
| Metric | OLED | ACAD |
|---|---|---|
| Price | $91.14 | $21.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | ★ $125.00 | $30.55 |
| AVG Volume (30 Days) | 631.8K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 9.25 | ★ 69.12 |
| EPS | ★ 0.76 | 0.02 |
| Revenue | $650,611,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $5.88 | $18.80 |
| Revenue Next Year | $10.36 | $11.70 |
| P/E Ratio | ★ $118.26 | $1,069.50 |
| Revenue Growth | 0.45 | ★ 40.45 |
| 52 Week Low | $83.64 | $19.69 |
| 52 Week High | $162.36 | $28.35 |
| Indicator | OLED | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 45.41 |
| Support Level | $85.79 | $21.04 |
| Resistance Level | $97.55 | $22.03 |
| Average True Range (ATR) | 3.55 | 0.58 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 50.04 | 28.67 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.